What to Expect From Corbus Pharmaceuticals in 2018
For a brief few weeks in 2017, it looked like Corbus Pharmaceuticals (NASDAQ: CRBP) could be making another big play after a terrific performance in the previous year. The stock gained more than 20% year to date by late March.
And then it all fell apart. Corbus announced results from a phase 2 study of anabasum in treating cystic fibrosis. Although the company viewed the results as positive, most outside observers didn't. Corbus stock is now down nearly 20% in 2017 despite its promising start.
Will the new year bring a return to glory for the biotech or a continuation of 2017? Here's what to expect from Corbus Pharmaceuticals in 2018.
Source: Fool.com
Corbus Pharmaceuticals Holding Inc. Stock
€49.80
3.810%
Based on 2 Buy predictions and 1 Sell predictions the sentiment towards Corbus Pharmaceuticals Holding Inc. is rather balanced.
At the moment Corbus Pharmaceuticals Holding Inc. has reached the predicted target price of 50 €, with a current price of 49.8 €.
